Trending...
- Announcing The Christina Hepburn Breast Cancer Support Campaign
- Boston: Demolition delay application: 1121 Dorchester Ave, Dorchester
- Entrinsik Promotes Robin Lamb to Vice President of Client Services
SAN JOSE, Calif. - BostonChron -- CPC Scientific Inc., a leading global peptide CRDMO (Contract Research, Development, and Manufacturing Organization) has invested in a new peptide API (Active Pharmaceutical Ingredient) manufacturing site, bringing many new jobs to Rocklin, California. The 41,000 sq ft facility located at 3880 Atherton Rd, Rocklin, CA 95765 will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity and will diversify CPC Scientific's supply chain.
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on Boston Chron
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on Boston Chron
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.
Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.
More on Boston Chron
- Boston: June 2022: Latest Updates from the Mayor's Office of Housing
- Who Will Be The 2022 Wimbledon Ladies' Champion?
- Ismail Sirdah' Guide To Landing Event Sponsorships
- Massachusetts: Governor Baker Signs Executive Order to Protect Access to Reproductive Health Care Services
- Web Traffic (Visitors) Guidelines: The Ultimate Beginner's Guide
Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.
"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.
More on Boston Chron
- Massachusetts: Baker-Polito Administration Announces Further Improvements to Supplier Diversity Efforts and Highlights Strides in Fiscal Year 2021
- Westside Finishing Inc. Awarded Products Finishing's Elite 2022 Top Shops Distinction
- Children's Shoe Brand joins Soles4Souls in Ukrainian Refugee Relief Efforts
- Rentable & SplitSpot collaborate to Create a Modern and Transparent Rental Experience
- The Data Economics Company announces partnership with Incradia to release the ReVerse franchise on Lydion-based Game Development Platform
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.
About CPC Scientific.
Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).
Source: CPC Scientific Inc.
0 Comments
Latest on Boston Chron
- Bacchus Wine & Spirits Jumps To Elite 'Top 20' Position In Beverage Dynamics Top 100 Retailers for 2022
- Hybrid-care Physical Therapy Platform Kins Announces $7.2M in Total Seed Funding to Accelerate Innovation in Care Delivery
- Wheels Up names Todd Smith Chief Financial Officer
- Boston-Based Golden Hearts Games, "The World's First Charity Casino," Surpasses $10M In Donations, Processes Over $6M in 2022 Alone as Over 50,000 Nonprofits Have Now Received Funding From the Platform
- PermaTherm 2022 Family Fun Day
- VBI Vaccines Announces Results of Annual General Meeting
- Boston: Mayor Wu Announces Installation of Mural Honoring Rita Hester in Allston
- Peak Physical Therapy & Sports Performance Named a Reader's Choice Award Winner across the Region
- New development in Ramsey called Williams Woods!
- EXECUTIVE COMPENSATION, EMPLOYMENT & BENEFITS PARTNER JOINS LATHAM & WATKINS IN BOSTON
- Ice Cold Liquid Hustle: Take on Summer With Dunkin's New Lineup of Iced Drinks
- Intercontinental Real Estate Corp./Cohen Asset Management Team To Buy Phoenix Industrial Property
- Top New Jersey Engagement Shoot Locations and couples who totally nailed it
- athenahealth Recognized with a 2022 KLAS Points of Light Award
- BEC Technologies RidgeWave® 7000 Series Achieves AT&T Certification
- Black CannaBusiness CEO Intensive Partners with Parallel on National Education Series
- Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
- Battery Ventures Makes Majority Investment in Titian Software
- "Summer Salsa By The Sea": held outdoors, by the ocean, in Beverly, MA